REPLY:

Author:

Lamarca Angela1ORCID,Santos‐Laso Alvaro2,Utpatel Kirsten3,La Casta Adelaida2,Stock Simone3,Forner Alejandro45ORCID,Adeva Jorge6,Folseraas Trine7,Fabris Luca8,Macias Rocio I. R.59ORCID,Krawczyk Marcin1011,Krawczyk Marek12,Cardinale Vincenzo13,Braconi Chiara14,Alvaro Domenico13,Evert Matthias3,Banales Jesus M.2515,Valle Juan W.1

Affiliation:

1. Medical Oncology/Institute of Cancer Sciences The Christie NHS Foundation Trust/University of Manchester Manchester United Kingdom

2. Department of Liver and Gastrointestinal Diseases Biodonostia Health Research Institute – Donostia University Hospital –, University of the Basque Country (UPV/EHU) San Sebastian Spain

3. Institute of Pathology University of Regensburg Regensburg Germany

4. BCLC group, Liver Unit Hospital Clínic Barcelona Barcelona Spain

5. National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd)III National Health Institute Carlos, Madrid Spain

6. Department of Medical Oncology Hospital Universitario 12 de Octubre Madrid Spain

7. Section of Gastroenterology and the Norwegian PSC Research Center, Department of Transplantation Medicine Oslo University Hospital Oslo Norway

8. Molecular Medicine University of Padua Padua Italy

9. Experimental Hepatology and Drug Targeting (HEVEFARM) Group University of SalamancaIBSAL Salamanca Spain

10. Department of Medicine II Saarland University Medical CentreSaarland University Homburg Germany

11. Laboratory of Metabolic Liver Diseases, Centre for Preclinical Research, Department of General, Transplant and Liver Surgery Medical University of Warsaw Warsaw Poland

12. Department of General, Transplant and Liver Surgery Medical University of Warsaw Warsaw Poland

13. Gastroenterology Sapienza University of Rome Rome Italy

14. Medical Oncology The University of Glasgow Glasgow United Kingdom

15. IKERBASQUEBasque Foundation for Science Bilbao Spain

Funder

European Cooperation in Science and Technology

Publisher

Wiley

Subject

Hepatology

Reference5 articles.

1. Does multiple intrahepatic cholangiocarcinoma worsen prognosis as “M1” stage?;Zhang XF;Hepatology,2021

2. Liver Metastases of Intrahepatic Cholangiocarcinoma: Implications for an Updated Staging System

3. AJCC Cancer Staging Manual

4. The cost of dichotomising continuous variables

5. Genomic profiling of multifocal intrahepatic cholangiocarcinoma reveals intraindividual concordance of genetic alterations;Lee SH;Carcinogenesis,2020

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3